相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
M. Fakih et al.
ANNALS OF ONCOLOGY (2021)
Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer
Jason T. Henry et al.
JCO PRECISION ONCOLOGY (2021)
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Marta Schirripa et al.
CLINICAL COLORECTAL CANCER (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
Kevin Lou et al.
SCIENCE SIGNALING (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Robert P. Jones et al.
BRITISH JOURNAL OF CANCER (2017)
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
D. P. Modest et al.
ANNALS OF ONCOLOGY (2016)
K-Ras protein as a drug target
Frank McCormick
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
Jens Neumann et al.
PATHOLOGY RESEARCH AND PRACTICE (2009)
A predictive probability design for phase II cancer clinical trials
J. Lack Lee et al.
CLINICAL TRIALS (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
